Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

FDA Approves Cabozantinib for Hepatocellular Carcinoma

Oncology Practice Insider

On January 14, 2019, the Food and Drug Administration approved cabozantinib (CABOMETYX®, Exelixis, Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read more